Recursion Pharmaceuticals

Home
United States
Salt Lake City, UT
Recursion Pharmaceuticals

Recursion is a clinical stage TechBio company decoding biology to industrialize drug discovery and radically improve lives.

Traditional drug discovery methods are inefficient and expensive – approximately 90% of all drugs in clinical trials ultimately fail to get approved and the total investment needed to develop each approved medicine exceeds $2 billion. This inefficiency occurs because biology is extraordinarily complex, and our industry has historically lacked the tools to understand how it functions. At Recursion, we’re harnessing the convergence of multiple breakthrough technologies that allow our scientists to explore uncharted areas of biology and unravel its complexity to navigate the path to better treatments. We have built a massive proprietary biological and chemical database that predicts trillions of relationships across biology and chemistry, many of which are not known in scientific literature. Our approach generates novel insights, broadens the scope of potential medicines, and truly industrializes drug discovery – increasing the scale, speed and efficiency of each step of the process. We believe our technology and approach has the potential to not only radically improve the lives of patients, but also change the landscape of drug discovery and development forever.

02/27/2026

Tomorrow is Rare Disease Day – an important reminder of just how prevalent rare diseases remain and how critical it is that we continue to leverage all of our tech tools and AI advances to find new treatments.

Rare diseases impact more than 300 million people worldwide – and 30 million in the U.S. – and just 5% of rare diseases have a treatment. Better approaches are needed.

🔹 On Tues., March 3, Recursion will host Utah Rare Disease Day at our Salt Lake City headquarters. We’ll welcome speakers from across the rare disease community – physicians, patients, and advocates – to share their stories of hope.

They include:
▪️ Erika Fox, Chief People and Impact Officer at Recursion
▪️ Oskar & Ava Szajnuk, rare disease patients with Rare and Undiagnosed Network (RUN)
▪️ Kelvyn Cullimore, President and CEO, BioUtah
▪️ Andy Roberston, executive director, BioHive
▪️ Justine Case, patient and advocate with Utah Rare Disease Advisory Council (RDAC)
▪️ Aaron Quinlin, professor at University of Utah
▪️ Sally Jo Zuspan, RN, MSN, director of research at University of Utah
▪️ Dr. Tracy George, president of ARUP Labs
▪️ Stacy Allen, parent and advocate at Intermountain Children’s Health
▪️ Januel Gomez, patient and Utah RDAC Council member

🤗 We’re looking forward to hearing from so many community members who are dedicated to raising awareness around rare diseases – and helping us to support patients and new treatments.

02/26/2026

Recursion CEO and President Najat Khan says the AI drug discovery industry is entering a new phase.

“It’s no longer about what models you build or about what collaborations you sign,” she says. “It’s about what you unlock that can actually drive better medicines, and Recursion is firmly pioneering that new phase.”

02/24/2026

Recursion announced yesterday that the company will participate in a number of upcoming investor conferences. These include:

▪️ TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026
▪️ Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026
▪️ Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026
▪️ KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026

👉 Check out the webcasts at ir.recursion.com.

02/23/2026

Recursion’s automated, integrated wet-dry lab operations will be featured as part of a Lightning Talk at GTC March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

Presenter Ira Hoffman, CEO of HighRes, will share how they are collaborating with us on the potential for self-driving, high-throughput labs with technologies including robotic perception, digital twins of lab environments, and natural language–driven lab orchestration. Other presenters include Fred Parietti, Co-Founder and CEO of Multiply Labs and Olga Ovchinnikova, Director of Product Management, Digital Labs, at Thermo Fisher Scientific.

“Recursion continues to push the frontier of drug discovery through the power of accelerated computing and AI,” says Kelleher, Senior Director, Global Head of Business Development, Healthcare and Life Sciences at . “This year at GTC, we’re collaborating across the ecosystem to move Physical AI from concept to reality, unlocking a new era of biological insight and therapeutic speed.”

👉 Learn more: https://ir.recursion.com/news-releases/news-release-details/recursion-be-featured-highres-lightning-talk-nvidia-gtc

👉 Check out the session at GTC: https://www.nvidia.com/gtc/session-catalog/sessions/gtc26-s81674/.

02/20/2026

🇬🇧 Accelerating AI adoption in the UK.

Recursion Chief Scientific Officer Dave Hallett was recently appointed as an AI Champion by the UK government. He’s one of 8 AI Champions and will be representing the life sciences industry, helping to inform, guide, and accelerate AI adoption plans in that space.

The 8 AI sector champions (other industries include clean energy, advanced manufacturing, professional and business services, digital and technology, advanced manufacturing, creative industries, and financial services) are responsible for:
▪️ Setting a clear national vision for how AI should be adopted in their sector
▪️ Building on the AI actions in their sector’s Industrial Strategy plan
▪️ Identifying practical steps to remove barriers and unlock investment

The champions will meet twice a year to report on progress and their activities will be published online.

Congrats to Dave and the other AI Champions!

👉 Learn more: https://delivery.ai.gov.uk/48/

02/18/2026

📣 Announcing our 4Q/FY 2025 business updates & (L)earnings Call

Recursion will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets.

🔹 We’ll host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT.

Tune in on YouTube: https://www.youtube.com/live/wtk81uUZ7ck

02/16/2026

In the latest episode of TechBio Talks, Recursion CEO and President Najat Khan, PhD talks to award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up To Cancer, Katie Couric, about personal motivations, the current state of AI drug discovery, and meaningful proof points like Recursion’s potential first-in-disease treatment for the rare disease FAP.

01/27/2026

▪️ 1 in 5 people will develop cancer.
▪️ 1 of 9 men and 1 of 12 women will die from cancer.
▪️ 90% of drugs that go into clinical trials fail.

Statistics like these are what fuel all of us at Recursion to create a better way to make new medicines. A new episode of ’s podcast Where the Internet Lives called “Mapping New Medicines” looks at the approach we’re taking – one that relies on massive proprietary datasets spanning biology, chemistry and patient data; supercomputing; and an end-to-end AI platform.

“I was frustrated by this slow, one-at-a-time approach” of traditional medicine, says co-founder and Board Chair Chris Gibson. “It felt like there had to be a better way.”

As he explains, each one of our cells contains about 20,000 genes that express around 400,000 proteins, with trillions of interactions inside the cells – “and we are made up of trillions of those cells.” That’s why biology is so complex and why, as CEO and President Najat Khan, PhD says, experts understand just 10-15% of biology. “How are we going to find a medicine if we don’t understand what’s driving a disease?” she asks.

Using that as a starting place, Recursion began employing a Google Maps approach to understanding biology – using data and AI to uncover how to take someone from disease state (Point A) to healthy state (Point B) in the fastest, best way possible.

The video takes you inside Recursion’s high throughput lab where we run millions of experiments each week, capturing cell images that are fed to and our supercomputer – moving more data per second through this platform than some of the leading social platforms.

As Recursion founding fellow and cancer survivor Michael Genin says, all of us love patients, are patients, or will be patients. “To dedicate our lives to changing the way drugs are discovered, to changing the future of medicine, there’s no greater pursuit.”

👉 Watch the full episode here: https://www.youtube.com/watch?v=o-8WCNb3BQY

AI future biology

01/26/2026

😊 The most important part of every JPM is the people.

Our annual event at the San Francisco Mint serves as a focal point for gathering investors, founders, industry leaders, and media to share ideas and get energized about the AI-driven future of drug discovery and development that we are building together.

Thank you to all who attended – including Katie Couric, Renee Gala, Reid Hoffman, Eric Topol, MD, and Eric Lefkofsky – and all who made this event possible. Looking forward to next year!

01/22/2026

Our TechBio Talks Live event at offered real insights about the state of AI drug discovery and the broader healthcare ecosystem.

Award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric led the discussions – including a fireside chat with Recursion CEO and President Najat Khan and a panel discussion with some of the people leading what Najat called “this new era of AI translation.” As she said: “It’s no longer, can we do this? It’s around what value does this actually create? And how does this show up in the lives of patients that are waiting?”

💡 Insights included:

▪️ From Renee Gala, President and CEO of Jazz Pharmaceuticals: “When you think about patient identification, there are so many advances now coming through AI that allow us to better identify patients, better identify what the biomarkers are.”

▪️ From Reid Hoffman, Co-founder, LinkedIn, Manas AI, & Inflection AI: “The idea when you have a target is not to spend 10 years seeing if it works,” but “how do you have AI help you actually force rank targets vis-a-vis feasibility, give you lots of variation of answers that you then cycle on very quickly?”

▪️ From Eric Lefkofsky, Founder & CEO, Tempus AI: “We’ve just built this giant self-learning machine that collects longitudinal clinical data, on about half the United States population who have cancer” and are “sequencing as many patients as we can...to figure out over time how to move from really targeted therapeutics to precision medicine.”

▪️ From Eric Topol, Chair, Department of Translational Medicine, Scripps Research: Although “Physicians are squeezed” and “clinicians are heading towards burnout and disenchantment,” AI is leading to a real flip – “And that’s what’s so exciting right now. Because we’re seeing for the first time, this is where AI, the near term, is really kicking in.”

Look for full versions of the talks on our YouTube channel: https://www.youtube.com/

TechBio

01/20/2026

At JPM, Recursion CEO and President Najat Khan, PhD spoke with Brad Loncar of BiotechTV about her vision for the company, Recursion’s competitive advantages, and the pipeline programs providing the clinical proof points for our platform’s novel insights.

🔹 Some highlights:

▪️ How do you want people to think about Recursion going forward?

“Fundamentally, Recursion is here to build differentiated medicines at scale for patients who are waiting. How we do it is different. We are the only AI native company that is end-to-end, leveraging AI across discovering novel biology, designing small molecules, and accelerating clinical development.”

▪️ You mentioned in your company presentation that your MEK inhibitor was the first example of finding something with the platform that surprised you. Tell us what that is.

“We found that this allosteric MEK 1/2 inhibitor actually reversed the disease to a healthy state in cellular models of FAP on our platform. That was that first biological insight. There was no connection back then that MEK inhibition could lead to rescuing APC loss of function. We then did all of the great in vivo work. We licensed that asset from a pharma company that had shelved it after studying it in solid tumors. And now we’re seeing the clinical data and what we see is rapid and durable polyp burden reduction – higher than what others have seen to date.”

👉 Watch the full interview: https://www.biotechtv.com/post/recursion-january-14-2026

01/16/2026

We were honored to host a packed TechBio Talks Live event at the San Francisco Mint at JPM with an introduction from CEO and President Najat Khan and a fireside chat with Najat and award-winning journalist, filmmaker, podcaster, and co-founder of Stand Up to Cancer, Katie Couric.

Katie moderated a panel discussion on the future of AI in healthcare and medicine featuring:
▪️ Renee Gala, President and CEO of Jazz Pharmaceuticals
▪️ Reid Hoffman, Co-founder, LinkedIn, Manas AI, & Inflection AI
▪️ Eric Lefkofsky, Founder & CEO, Tempus
▪️ Eric Topol, Chair, Department of Translational Medicine, Scripps Research
They discussed the best places to deploy capital to drive AI innovation in healthcare; how to distinguish clinical impact from AI hype; and how technology is positioned to impact patients.

Thank you to all the panelists and guests who attended – we’ll be sharing more highlights and videos from this incredible night in the weeks to come!

Address

41 S Rio Grande Street
Salt Lake City, UT
84108

Website

http://www.recursion.com/

Alerts

Be the first to know and let us send you an email when Recursion Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Recursion Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Salt Lake City?

Our Story

Our dynamic team combines innovative biological science with advanced computational algorithms to discover new therapeutic opportunities for rare genetic diseases. We use high-throughput genetic manipulation to model many diseases in multiple human cell types quickly and efficiently. Thousands of cells representing each model are imaged using high-throughput automated microscopy. We use automated image segmentation systems to quantify hundreds or thousands of structural relationships in tens of thousands of cells for every disease we model. Our proprietary informatics approaches enable us to identify the critical disease-specific changes associated with each disease model. Once we have quantified the phenotypic fingerprint (phenoprint) for a disease, we model it en-masse in thousands of wells and evaluate the ability of thousands of drugs to rescue the disease-specific structural perturbations back to 'health'.